Presentation of Research Findings at the International Medical Congress “AMWC Japan 2025,” Held in November 2025
Sharing Multidisciplinary Clinical Insights on a Global Stage—from Lower Eyelid Treatments to Hyaluronic Acid Injections and Cryolipolysis
IRVINE, Calif. -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced that three physicians from clinics supported by the Company presented their research findings at the international medical congress “AMWC Japan 2025.”
AMWC Japan is an international medical conference held as the Japanese edition of AMWC (Aesthetic & Anti-Aging Medicine World Congress), the world's largest aesthetic and anti-aging medical congress headquartered in Monaco. It serves as a platform for sharing cutting-edge knowledge in fields such as aesthetic medicine, dermatology, and regenerative medicine, bringing together specialists and researchers from around the world. Through education, research, and technical exchange, it aims to further elevate medical standards. Held over two days starting Saturday, November 8, 2025, “AMWC Japan 2025” saw participation from numerous medical professionals and industry stakeholders both domestically and internationally. The event featured presentations on evidence-based treatment approaches, educational system development, and practical initiatives for enhancing safety, fostering lively discussions from an international perspective.
At this conference, Dr. Ayaka Nishikawa, Head of Dermatology at Shonan Beauty Clinic; Dr. Atsushi Hayashi, Director of Shonan Beauty Dermatology Gotanda Branch; and Dr. Kanako Misono, of Shonan Beauty Clinic Shinjuku Main Branch, were invited to present based on high recognition of their past conference presentations and clinical achievements. Dr. Nishikawa presented the latest findings on minimally invasive combination therapy for the lower eyelid and product-specific applications of PN (polynucleotide) injection therapy. Dr. Hayashi shared a large-scale study on safety education systems for hyaluronic acid injections. Dr. Misono introduced practical approaches to enhance safety and reproducibility in fat cryotherapy, including safety management and communication. Each presentation garnered significant interest and resonance from attendees.
Now that aesthetic medicine has become a more accessible option, it is precisely why we must return to its fundamental principles and continually question its role as a medical practice. At SBC Medical Group, we have actively built platforms for learning and knowledge sharing through academic activities, in addition to scientifically verifying clinical findings, standardizing techniques, and systematizing education. Moving forward, we will continue to promote information exchange through academic activities, striving to standardize medical practices and enhance safety, with the goal of building aesthetic medicine that earns society's trust.
Overview of AMWC Japan 2025
Venue: The Prince Park Tower Tokyo
Dates: November 8 (Sat) – November 9 (Sun), 2025
Official Website: https://www.amwc-japan.com/
Presentation Titles
Dr. Ayaka Nishikawa (Chief Director of Dermatology, Shonan Beauty Clinic)
・ Efficacy and Safety of Minimally Invasive Combination Treatments for the Lower Eyelids
・ Clinical Experience and Product-Specific Applications of PN (Polynucleotide) Injections within Our Group: 2025 Update
Dr. Atsushi Hayashi (Director, Shonan Beauty Dermatology Gotanda Clinic)
An Educational Framework to Reduce Adverse Events in Hyaluronic Acid Injections:
Findings from a Large-Scale, Multi-Center Study of 317,490 Cases
Dr. Kanako Misonou (Shonan Beauty Clinic Shinjuku Main Branch)
Safety of Cryolipolysis: Clinical Data and Communication for Safe Practice
About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatment, dentistry, AGA (hair restoration), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
For more information, visit https://sbc-holdings.com/
Contacts
SBC Medical Group Holdings Incorporated (Asia)
Hikaru Fukui / Head of Investor Relations E-mail: ir@sbc-holdings.com
Daisuke Murakami / Public Relations Officer E-mail: pr@sbc.or.jp
ICR LLC (In the US)
Bill Zima / Managing Partner Email: bill.zima@icrinc.com